Inari Medical to Announce Third Quarter 2021 Financial Results
Inari Medical, Inc. (NASDAQ: NARI) announced it will release its third quarter financial results on November 9, 2021. A conference call and webcast will follow at 1:30 PM PT / 4:30 PM ET to discuss these results and recent highlights. Inari specializes in medical devices for treating venous diseases, featuring FDA-cleared systems such as ClotTriever for deep vein thrombosis and FlowTriever for pulmonary embolism. Interested parties can join the call through provided phone numbers or access the webcast via Inari's investor relations website.
- FDA-cleared and CE Mark approved ClotTriever and FlowTriever systems for VTE treatment.
- None.
IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its third quarter financial results on Tuesday, November 9, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 7775678. The live webinar of the call may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
When will Inari Medical release its Q3 financial results?
What time is the Inari Medical Q3 earnings call?
How can I access the Inari Medical Q3 earnings call?
What products does Inari Medical focus on?
